Javier Pinilla-Ibarz

Hematology — Moffitt Cancer Center, United States

LeadR Profile

Javier Pinilla-Ibarz Moffitt Cancer Center United States
1 621 ScienceLeadR Reputation 1621
Network Map

Hematology

Subspecialties: Oncology - Immunology - Transplantation

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1998 - 2026

Source: PubMed

Moffitt Cancer Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 404

Citations

Citations: 10 141 1st author: 27 Last author: 98 Unique author: 4


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Plasmablastic Richter Transformation of Chronic Lymphocytic Leukemia With Aberrant Epithelial Marker Expression Presenting as a Pleural Effusion: A Diagnostic Challenge.
pleural effusion, lymphoma, lymphoma, large b-cell, diffuse, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid
Case Rep Pathol20260
Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel.
cells, lymphoma, b-cell, lymphoma, therapeutics, palliative care, memory, b-lymphocytes
Support Care Cancer20260
A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T-Cell Lymphoma.
cells, lymphoma, azacitidine, transplants, therapeutics, t-lymphocytes, allografts, lymphoma, t-cell
Hematol Oncol20260
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.
cells, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, therapeutics, mutation, b-lymphocytes
Blood Cancer J20260
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma.
treatment switching, lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, therapeutics, hematologic diseases
Expert Rev Hematol20260

Clinical Studies 17

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 1 7
Phase 2 4
Phase 3 3
N/A 1
Phase 1/Phase 2 1
Phase 4 1

By status:

Completed 13
Active not recruiting 2
Recruiting 1
Terminated 1

By type:

Interventional 17

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 1
multicentricup10 10

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
AS 1763 in Patients With Previously Treated CLL SLL or Non Hodgkin Lymphoma
NCT05602363 — cells, lymphoma, follicular, hodgkin disease, lymphoma, b-cell, lymphoma, neoplasms, leukemia, lymphocytic, chronic, b-cell, lymphoma, b-cell, marginal zone, leukemia, tablets, leukemia, lymphoid, lymphoma, mantle-cell, waldenstrom macroglobulinemia, lymphoma, non-hodgkin, b-lymphocytes
Phase 1Recruiting2023

LeadR Networks

Main global connection map